- Home
- BRLT vs QNCX Comparison
BRLT vs QNCX Comparison
Compare BRLT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | QNCX |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 19.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRLT | QNCX |
|---|---|---|
| Price | $1.17 | $0.93 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | 65.7K | ★ 1.4M |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | $0.33 |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.11 | $0.08 |
| 52 Week High | $3.10 | $4.55 |
Technical Indicators
Market Signals| Indicator | BRLT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 41.03 |
| Support Level | $1.11 | $0.79 |
| Resistance Level | $1.37 | $0.98 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 2.50 | 12.79 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.